New company is attracted to magnetic approach to treating metabolic disorders
A handful of companies received a green light from the FDA last year to launch devices intended to treat metabolic disorders, including obesity and type 2 diabetes, and several other technologies are in various stages of development. One of the most interesting aspects of this competitive market is the wide array of approaches these companies are taking to treat this patient population.
Boston Scientific flies the W flag
It took 10 years but Boston Scientific (BSX) may have finally overcome its ill-advised 2006 Guidant acquisition. The company's shares hit a decade high Wednesday, at one point spiking nearly 12 percent to $22.05 after knocking its first quarter sales out of the park. (MDD Perspectives)
Growing evidence supports clinical potential of new cancer tests
With a market opportunity in the billions (as much as $20 billion by some estimates), diagnostic companies are rushing the liquid biopsy floodgates with new tests designed to make finding and monitoring cancer as easy as a blood draw or urine sample. This week, in a two-part series, Medical Device Daily will explore both the business opportunities and the clinical potential of this growing market.